GVGolla Varshitha

Golla Varshitha

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Golla Varshitha has a total of 53 co-authors. Here are the top co-authors by number of shared publications:

  • Lakshmi Venkata Simhachalam Kutikuppala

    Department of General Surgery Dr YSR University of Health Sciences Vijayawada Andhra Pradesh India

    4 shared publications
  • Arup Kumar Misra

    Department of Pharmacology All India Institute of Medical Sciences (AIIMS) Mangalagiri Andhra Pradesh India

    3 shared publications
  • Sushil Sharma

    Department of Pharmacology All India Institute of Medical Sciences (AIIMS) Mangalagiri Andhra Pradesh India

    3 shared publications
  • Gaurav Rangari

    Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India

    2 shared publications
  • L V Simhachalam Kutikuppala

    Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India

    2 shared publications
  • Pavani Saggurthi

    Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Mangalagiri, Andhra Pradesh, India

    2 shared publications

Latest Publications

  • Open Access

    An Unusual Case Presentation on Docetaxel Induced Lung Injury

    by Soorej Balan Kaliyath, S. Pavani, Arup Kumar Misra, A. Kesav Ramgopal, S. Yugandhar, Sushil Sharma, L. V. Simhachalam Kutikuppala, Golla Varshitha

    Docetaxel can rarely cause acute interstitial lung injury early in therapy. New‐onset cough, fever, or dyspnea after chemotherapy should prompt immediate evaluation, exclusion of infection, and high‐resolution CT imaging. Early drug withdrawal and timely corticosteroid therapy can result in rapid clinical recovery and prevent serious morbidity.

  • Open Access

    Exploring the history of an unsung hero in pioneering biomedical research: Dr Yellapragada Subbarow

    by L V Simhachalam Kutikuppala, Sushil Sharma, C Madhavrao, Gaurav Rangari, Arup Kumar Misra, Srinivasa Rao Katiboina, Pavani Saggurthi, Golla Varshitha

    An abstract is unavailable. This article is available as a PDF only.


  • Study on MTHFR (C677T & A1298C) Gene Polymorphisms in the Condition of Glucose Intolerance During Pregnancy

    by Bunga Papa Kusuma, D. Lakshmi Lalitha, Nagarjuna Sivaraj, Vijaya Sirisha Balaga, Arun Kumar Rao Panchanani, L V Simhachalam Kutikuppala, S. Sai Roshan, K. Kavya, Golla Varshitha

    Introduction: Gestational diabetes mellitus (GDM) is a prevalent medical complication in pregnancy, characterized by glucose intolerance. The global expected prevalence of GDM is approximately 15.1%. This study builds upon previous research by investigating elevated hematological parameters and exploring MTHFR gene polymorphisms in GDM.Materials and Methods: This study included 304 pregnant women, comprising 152 patients with GDM and an equal number of normal pregnant women. Employing PCR‐RFLP techniques, we identified MTHFR gene polymorphisms (C677T & A1298C) associated with gestational diabetes.Results: Significant associations were found in gestational age and platelet count, indicating their relevance to GDM risk. The odds ratios for both MTHFR A1298C (p value: 0.034; OR = 0.7; 95% CI: 0.5021–0.9758) and MTHFR C677T (p value: 0.008; OR = 0.5453; 95% CI: 0.3292–0.9011) gene polymorphisms demonstrated an increased risk of GDM development.Conclusion: The study reveals that elevated platelet count and polymorphs increase the risk of developing GDM in pregnant women. Gestational age also plays a role. The study also finds a link between the MTHFR C677T SNP and the MTHFR A1298C gene polymorphism and the risk of gestational diabetes in Andhra Pradesh. This gives us new information about genetic and hematological factors.

  • Open Access

    Implementation of the pharmacovigilance database in the usage of antibiotics in a tertiary care hospital: A pilot study

    by Karri Juhu Kiran Krushna, Arup Kumar Misra, Pavani Saggurthi, Sushil Sharma, C. Madhavrao, Gaurav Rangari, L. V. Simhachalam Kutikuppala, Golla Varshitha

    Background: Antimicrobial resistance (AMR) has evolved into a severe public health issue that defies all current control strategies and needs multidisciplinary, creative solutions. Antimicrobial stewardship (AMS) activities demand a set of tools and abilities that can be used by health systems. In view of the growing AMR and the difficulty for the surveillance of it in the developing country, this study was conducted to incorporate pharmacovigilance (PV) in the AMS program.Materials and Methods: A cross‐sectional pilot study was conducted to collect the PV database of antimicrobials induced adverse drug reactions (ADR) from the Adverse Drug Reactions Monitoring Center (AMC) of the institute for a period of 2 months from August 2022 to September 2022. The information from the database was analyzed to estimate the usage of antibiotics from the PV database from AMC and classified it under the Anatomical Therapeutic Chemical, to assess the rationality of the antimicrobial's usage based on “Access,” “Watch,” and “Reserve” (AWaRe) classification, and to assess the ADR of the antibiotics. The analysis was done by using the SPSS version 20.0 for Windows.Results: The results showed that the prevalence of ADRs were more in adults’ population with preponderance in female. The antibiotics usage was as per with World Health Organization standard and most of the antibiotics used were from the Access group of AWaRe classifications. Tetracyclines and penicillins were the most used antibiotic group of drugs. The number of patients included in the study was 70. Most of the causality assessment was “possible” (62.85%). In the study, almost 90% of the drug was withdrawn and 70% of the patients were in the recovering stage.Conclusion: Using existing PV approaches to address usage of antibiotics and AMR issues would allow PV to progress as a field, and governments will get a stronger return on their PV investments.


  • Open Access

    Purtscher's like retinopathy - A rare ocular complication of acute pancreatitis

    by Havil Stephen Alexander Bakka, Perumalla Karthik Babu, Simhachalam L.V. Kutikuppala, Ramana M.V. Reddy, Golla Varshitha

    Introduction and importance: Purtscher retinopathy is the rare form of occlusive microvasculopathy, characterized by multiple retinal white areas around the optic nerve head and fovea with paravascular clearing and may be related to intraretinal hemorrhages. Acute Pancreatitis (AP) is one of the most common gastrointestinal reasons for hospital admissions globally. The complications of Acute Pancreatitis may include Purtscher's-like retinopathy, which has a low incidence rate of less than 0.24 instances per million cases. This case report highlights the value of thorough medical history taking and examination, and it apprises the consideration of ophthalmological manifestation in patients of Acute Pancreatitis. Case presentation: A 34-year-old female came to the emergency room due to intense abdominal pain associated with nausea and vomiting, which worsened over the last 24 h. The pain was described as continuous, sharp, and cramping-like in the upper abdomen, radiating to the back. Lab tests revealed elevated serum amylase and lipase levels, indicating pancreatitis, along with slight leukocytosis. A contrast-enhanced CT scan confirmed acute pancreatitis with mild inflammation and enlargement of the pancreas. Two days after admission, the patient experienced a sudden and painless loss of central vision in both eyes. There was no history of trauma or any other significant relevant history, other than pancreatitis. The ophthalmologist's examination found reduced visual acuity (6/60 in the right eye, 3/60 in the left eye), normal corneas, and anterior chambers. Discussion: Inkeles and Walsh established the first link between acute pancreatitis and Purtscher-like retinopathy when they reported three cases of the distinctive retinal appearance in individuals with acute pancreatitis in 1975. Conclusion: The recovery and prognosis in cases of Purtscher-like retinopathy is variable and further research is required to ascertain the usage of corticosteroids and pentoxifylline in improving the course of a patient's with Purtscher's-like retinopathy. Highlights:


  • Open Access

    An unusual presentation of penile fracture with complete transection of urethra: a case report

    by Vasanth Dunna, Srinivasa Rao Giduturi, K S N Chary, L V Simhachalam Kutikuppala, Anna Mary Jose, Varshitha Golla

    Penile fracture is one such urologic emergency that occurs when the penis is struck bluntly during sexual activity, and in less than 5–10% of cases, the concurrent urethral damage is evident, but complete transection is very rare. A 37-year-old male presented with a history of ‘snap’ sound and immediate detumescence of penis during intercourse, when he fell and hit the pubic bone of his partner. There was acute retention of urine, an attempt to pass a catheter failed and the patient underwent supra-pubic catheterization. On examination, there was classical ‘eggplant deformity’ of the penis with blood at the tip of the meatus. MRI showed a tunical tear on both sides at the penoscrotal junction with indistinct urethra and extensive hematoma in the proximal penile shaft. Surgical management was successfully done by anastomotic urethroplasty and cavernosal repair.


  • Open Access

    ST2 levels and neurodegenerative diseases: is this a significant relation?

    by Himanshu Arora, Binish Javed, L V Simhachalam Kutikuppala, Mayuri Chaurasia, Kaarvi Khullar, Shreevikaa Kannan, Varshitha Golla

    Interleukin-33 (IL-33), belonging to the interleukin-1 cytokine family, has a decoy receptor soluble ST2 (sST2). IL-33 is found in oligodendrocytes and astrocytes and is involved in central nervous system healing and repair, whereas ST2 is found in microglia and astrocytes. Some studies have found a link between changes in the IL-33/ST2 pathway and neurodegenerative disorders. This review article investigates the relationship between the interleukin-33 (IL-33)/ST2 pathway and neurodegenerative disorders. It was discovered that soluble st2 levels were increased. Furthermore, IL-33 levels were found to be lower in many neurodegenerative diseases such as Alzheimer’s and amyotrophic lateral sclerosis (ALS). The association with other disorders, such as ankylosing spondylitis, multiple sclerosis, and systemic lupus erythematosus (SLE), was also observed. Various studies suggest that ST2/IL-33 signalling may be pivotal in the disease modulation of neurodegenerative disorders. The serum sST2 level test can be useful in determining the inflammatory status and severity of illness in many neurodegenerative disorders. In this review, we will discuss recent findings concerning the interleukin-33 (IL-33)/ST2 pathway and its role in the diagnosis and treatment of diseases with neurodegeneration.


  • Open Access

    Role and application of CRISPR-Cas9 in the management of Alzheimer’s disease

    by Nilay Soni, Indrani Kar, Jadav Dhruvkumar Narendrasinh, Sanjay Kumar Shah, Lohini Konathala, Nadine Mohamed, Meet Popatbhai Kachhadia, Mitul Hareshkumar Chaudhary, Vyapti A. Dave, Lakshya Kumar, et al.

    Alzheimer’s disease (AD) is a serious health issue that has a significant social and economic impact worldwide. One of the key aetiological signs of the disease is a gradual reduction in cognitive function and irreversible neuronal death. According to a 2019 global report, more than 5.8 million people in the United States (USA) alone have received an AD diagnosis, with 45% of those people falling into the 75–84 years age range. According to the predictions, there will be 15 million affected people in the USA by 2050 due to the disease’s steadily rising patient population. Cognitive function and memory formation steadily decline as a result of an irreversible neuron loss in AD, a chronic neurodegenerative illness. Amyloid-beta and phosphorylated Tau are produced and accumulate in large amounts, and glial cells are overactive. Additionally, weakened neurotrophin signalling and decreased synapse function are crucial aspects of AD. Memory loss, apathy, depression, and irritability are among the primary symptoms. The aetiology, pathophysiology, and causes of both cognitive decline and synaptic dysfunction are poorly understood despite extensive investigation. CRISPR/Cas9 is a promising gene-editing technique since it can fix certain gene sequences and has a lot of potential for treating AD and other human disorders. Regardless of hereditary considerations, an altered Aβ metabolism is frequently seen in familial and sporadic AD. Therefore, since mutations in the PSEN-1, PSEN-2 and APP genes are a contributing factor to familial AD, CRISPR/Cas9 technology could address excessive Aβ production or mutations in these genes. Overall, the potential of CRISPR-Cas9 technology outweighs it as currently the greatest gene-editing tool available for researching neurodegenerative diseases like AD.


  • Open Access

    Bromocriptine: does this drug of Parkinson’s disease have a role in managing cardiovascular diseases?

    by Lakshmi Venkata Simhachalam Kutikuppala, Sushil Sharma, Madhavrao Chavan, Gaurav Rangari, Arup Kumar Misra, Sai Ram Innamuri, Tejus Vijayakumar, Golla Varshitha, Tejus V

    Cardiovascular disease (CVD) is the most common cause of morbidity and mortality worldwide. Bromocriptine is a partial antagonist for D1 dopamine receptors while also serving as a selective agonist on D2 dopamine receptors as a dopamine receptor agonist. Apart from prolactin inhibiting action, bromocriptine has some beneficial effects on the blood pressure, plasma norepinephrine levels and vascular resistance. Dopamine D2 receptor activation of bromocriptine is associated with the antihypertensive effect, which lowers blood pressure via inhibiting sympathetic nerve activity and Na/K ATPase activity. Plasma levels of the pro-inflammatory cytokines such as interleukin (IL)-1B and IL-18, chemokine CCL2/ MCP-1/, and the pro-inflammatory hormone prolactin, all of which are elevated and linked to accelerated cardiometabolic illness, were decreased because of bromocriptine therapy. The most common side effects of Bromocriptine use are dizziness, nausea, headache, vomiting and hypotension. Bromocriptine is mainly contraindicated in patients with syncope with hypotension, psychosis, and type I diabetes mellitus. The authors suggest that developing therapies directed to increase D2 receptor expression and function by drugs like Bromocriptine can provide practical and novelistic approaches to prevent and manage myocardial and renal injury in the cardiovascular disease patients.